HELP:NASDAQ
Cybin Inc
US$5.16
0.00%
(0.00) 1D
US$5.26
arrow_upward
+1.94% (+0.10)today개장 전 거래
휴장: 4월 28일, 오후 4시 0분 0초 GMT-4 · USD
search
모든 종목 코드
1D
5D
1M
6M
YTD
1Y
5Y
최대
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoHELP의 주요 통계 생성 중...
평균 거래량
112.95만
거래량
1.50만
52주 최고가
US$8.97
52주 최저가
US$4.29
베타
1.03
유통 주식수
5003.60만
직원 수
50
뉴스 기사
웹 소스 기반
프로필
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, HLP003, HLP004, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
Cybin Inc에 관한 정보